SRRK

The past six months have seen several significant events impacting SRRK's stock price. On September 14, 2026, Scholar Rock announced FDA approval of ISEMBYLD™ (apitegromab-mstn) for spinal muscular atrophy, ahead of its PDUFA date, though a clarification on September 15, 2026, noted post-marketing requirements for a pregnancy safety study and fracture reporting. For European regulatory updates, Scholar Rock resubmitted its Marketing Authorisation Application (MAA) for apitegromab to the European Medicines Agency (EMA) on October 8, 2026, following a voluntary withdrawal in August 2026 due to a manufacturing facility classification, now utilizing an alternate U.S.-based fill-finish facility. As of October 9, 2026, SRRK shares had decreased by 4.2% year-to-date, with a fall of -12.67% in the previous week and -21.98% in the last month. The company reported Q2 2026 adjusted EPS of -$0.84, which beat consensus estimates and led to a 4.35% premarket rise. Several analysts updated their price targets, with Piper Sandler reiterating an Overweight rating and a $75 price target, Truist Securities raising its target to $77, JPMorgan increasing its target to $70, UBS maintaining a Buy rating with a $60 price target, and Raymond James reiterating a Strong Buy rating with a $72 price target. Additionally, the company reported new employee inducement grants under Nasdaq Listing Rule 5635(c)(4) on September 21, 2026, and in August 2026.